US/UK/Canada

Share

Contacts

  • Emma Rheborg

    Head of Communication


    Svärdvägen 3A SE-182 33 Danderyd Sweden
    +46733136217
    http://asker.com

    • Links

    Pick a time period -
    Tags ( Active)

    Agreement to discontinue acquisition of Kirstine Hardam

    Asker Healthcare Group and KMT Medical Europe Limited, the owner of Kirstine Hardam A/S (“Hardam”), have mutually agreed to discontinue the transaction of Hardam that was announced in June 2025.“Hardam is a well-run company with a strong position in the Danish healthcare market, but after a long closing process, we have, in the best interest of the company, agreed with the seller to stop the process. We are now turning our focus to other attractive opportunities in our strong pipeline of acquisition targets across Europe,” says Johan Falk, CEO of Asker Healthcare Group. For further

    Interogo Long-Term Equity has issued call options to Asker’s Chair of the Board

    The Board of Directors of Asker Healthcare Group AB (publ) (“Asker”) has been informed that Asker’s largest shareholder, Interogo Long-Term Equity, through Strukturfonden HC15 AB (“Interogo”), has issued call options in Asker to the Chair of the Board, Mikael Stöhr.In total, 291,970 options, each entitling the holder to acquire one share, have been acquired by Mikael Stöhr at a price corresponding to market value of the options on the transaction date, based on a valuation conducted by an independent valuation institute applying the Black & Scholes valuation model. The total market value of

    Bulletin from Annual General Meeting in Asker Healthcare Group AB (publ) on 7 May 2026

    Asker Healthcare Group AB (publ) has held its Annual General Meeting (AGM) today on 7 May 2026. The AGM was held at Näringslivets Hus in Stockholm, Sweden, with the option for shareholders to exercise their voting rights by advance voting (postal voting).Adoption of the profit and loss statement, the balance sheet, and dividend The AGM adopted the profit and loss statement and the balance sheet, as well as the consolidated profit and loss statement and the consolidated balance sheet. In accordance with the Board’s proposal, the AGM resolved that a dividend of SEK 0.39 per share should be

    Interim report 1 January–31 March 2026

    Strong start to the year 1 January–31 March 2026 · Net sales amounted to SEK 4,521m (3,995), up 13%. · Adjusted EBITA amounted to SEK 442m (364), up 21%. · The adjusted EBITA margin was 9.8% (9.1). · EBIT amounted to SEK 310m (237), and profit for the quarter amounted to SEK 197m (95). · Earnings per share before and after dilution amounted to SEK 0.50 (0.19). · Return on net working capital (EBITA/NWC) amounted to 67.7% (66.5). · Cash flow from operating activities amounted to SEK 419m (109). · During the quarter, Asker signed two acquisition agreements: GHC/

    Invitation to Asker Healthcare Group’s Q1 2026 webcast

    Asker Healthcare Group will publish its interim report for January – March 2026 on Wednesday 6 May, at 08:10 CEST.Asker invites investors, analysts and media to a webcast presentation on the same day at 10:00 CEST. Asker’s CEO Johan Falk and CFO Thomas Moss will present and comment on the report, followed by a Q&A session. You will find the webcast link via Q1 2026 Webcast .  To participate via phone and ask questions, please register via Call Access 

    Asker publishes Annual and Sustainability Report for 2025

    Asker Healthcare Group has published its Annual and Sustainability Report for 2025.[Asker_press_release_image_260416_EN.jpg] CEO Johan Falk comments on Asker’s development: 2025 has been yet another good year with total adjusted EBITA growth of 17 per cent and a high level of activity. At the beginning of the year, Asker was listed on Nasdaq Stockholm – an important milestone in our journey. At the same time, our focus has remained the same: to create profitable growth through our "twin engine" model, both through organic growth and carefully selected acquisitions, thereby

    Change in the number of shares and votes in Asker Healthcare Group

    As of 31 March 2026, the number of shares in Asker Healthcare Group AB (publ) (“Asker”) amounts to 383,706,497 shares. All shares are ordinary shares. The total number of votes in Asker amounts to 383,706,497 votes.The increase in the number of ordinary shares and votes is due to the issuance of 670,000 Class C shares earlier in March. The Class C shares have been issued for the purpose of ensuring fulfillment of commitments under Asker's long-term performance-based investment share program. The Class C shares have been reclassified into ordinary shares pursuant to the conversion clause in

    Notice of Annual General Meeting in Asker Healthcare Group AB (publ)

    Asker Healthcare Group AB (publ), Reg. No. 559184-9848 (“Asker” or the “Company”), with its registered office in Danderyd, gives notice of the Annual General Meeting to be held on 7 May 2026 at 13.30 CEST at Industrisalen, Näringslivets hus, Storgatan 19, SE-114 51 Stockholm, Sweden. Registration starts at 13.00 CEST.   Right to participate in the Annual General Meeting and notice of participation   Participation in the Annual General Meeting at the venue   A shareholder who wishes to participate in the Annual General Meeting at the venue, in person or represented by a

    Acquisition of RMS Medical Devices

    Asker Healthcare Group has signed an agreement to acquire 100 per cent of the shares in RMS Medical Devices (“RMS”), a fast-growing medical device distributor based in Belgium.[Asker_press_release_image_260320.jpg] “RMS is a highly respected company with 40 years of experience in the Belgian healthcare market and a strong reputation for clinically driven innovation. Their expertise in supporting hospitals and healthcare professionals as they integrate new solutions into daily practice aligns perfectly with Asker’s ambition to build healthier communities. With a strong portfolio of high-

    Issuance, repurchase and reclassification of Class C shares under incentive program in Asker Healthcare Group

    Today, on 9 March 2026, the Board of Directors of Asker Healthcare Group AB (publ) (“Asker”) has resolved to issue 670,000 new Class C shares and to immediately thereafter repurchase and reclassify all of the issued Class C shares into ordinary shares.The purpose of the issuance, repurchase and reclassification is to ensure the delivery of ordinary shares to employees within the Asker group in accordance with Asker’s long-term performance-based investment share program, which was adopted by the Extraordinary General Meeting on 27 August 2025 (“LTIP 2025”). By virtue of the authorization

    Nomination Committee’s proposal for Board of Directors of Asker ahead of the 2026 Annual General Meeting

    The Nomination Committee of Asker Healthcare Group AB (publ) (“Asker”) proposes that Mikael Stöhr be elected as new Chair and member of the Board of Directors, and that Joachim Zetterlund be elected as new member of the Board of Directors at the Annual General Meeting on 7 May 2026. Asker’s current Chair of the Board, Håkan Björklund, has declined re-election due to a desire to reduce the number of assignments. Board member Martin Lagerblad has also declined re-election. The Nomination Committee proposes re-election of the other Board members Birgitta Stymne Göransson, Karl Petersson,

    Year-end report 1 January–31 December 2025

    An eventful year with continued robust growth 1 October–31 December 2025 · Net sales amounted to SEK 4,676m (4,303), up 9%. · Adjusted EBITA amounted to SEK 470m (406), up 16%. · The adjusted EBITA margin was 10.0% (9.4). · EBIT amounted to SEK 281m (287), and profit for the quarter amounted to SEK 136m (108). · Earnings per share before and after dilution amounted to SEK 0.34 (0.24). · Return on net working capital (EBITA/NWC) amounted to 67.0% (67.4). · Cash flow from operating activities amounted to SEK 568m (459). · During the quarter, Asker signed

    Changes in Asker’s Group Management Team

    Lovisa Hedin, currently M&A Director at Asker has been appointed new Head of M&A as of 1 April and Kerstin Mjömark, currently Head of HR, has been appointed Head of HR and ESG from the same date. Ola Nordh, currently Head of M&A, and Sanna Norman, currently Head of ESG will leave Asker later this year after ensuring a smooth transition.[Lovisa Hedin Kerstin Mjömark.png] “I’m pleased to welcome Lovisa to our Group Management Team. She has, alongside Ola Nordh, over the past four years been part of establishing the M&A process, where our local companies and management teams drive the M&A

    Invitation to Asker Healthcare Group’s Year-End Report 2025 webcast

    Asker Healthcare Group will publish its Year-End Report for 2025 on 10 February, at 08:10 CET.Asker invites investors, analysts and media to a webcast presentation on the same day at 10:00 CET. Asker’s CEO Johan Falk and CFO Thomas Moss will present and comment on the report, followed by a Q&A session. You will find the webcast link via Year-End Report 2025 .  To participate via phone and ask questions, please register via Call Access . The presentation

    Acquisition of GHC and MPF

    Asker Healthcare Group has signed an agreement to acquire 100 per cent of the shares in German Healthcare GmbH and Medicalprodukte Vertrieb Flensburg GmbH (“GHC/MPF”), two interlinked medical supplies companies within the homecare segment in Germany.[Asker_press_release_260107.jpg] “The acquisition of GHC/MPF is a very good fit with our ambition to grow within the homecare segment in Germany. The company has a strong and growing position in its niche, and its portfolio of high-quality private label products within incontinence and urology is attractive to many of our other companies

    Acquisition of Van Heek Medical

    Asker Healthcare Group has signed an agreement to acquire 100 per cent of the shares in Allion B.V. (“Van Heek Medical”), a leading manufacturer and distributor of medical supplies in the Benelux region.[Asker_press_release_251216.jpg] “We continue to strengthen our offering in the Benelux and are pleased to welcome the experienced team from Van Heek Medical to the Asker family. Their focus on servicing the market with high-quality, affordable products will complement Asker’s current footprint in the region well. We have followed this company for quite some time and are impressed by

    Bulletin from Extraordinary General Meeting in Asker Healthcare Group AB (publ) on 9 December 2025

    Asker Healthcare Group AB (publ) has held an Extraordinary General Meeting (EGM) today on 9 December 2025. The EGM was held at Advokatfirman Vinge’s office in Stockholm, Sweden, with the option for shareholders to exercise their voting rights by advance voting (postal voting).The EGM resolved that the Board of Directors shall continue to consist of six members. The EGM further resolved that board and committee fees shall be paid to all board members, regardless of their dependence, pro rata from and including the EGM to and including the Annual General Meeting 2026. Finally, Karl Petersson

    Acquisition of Cardio Dépôt

    Asker Healthcare Group has acquired 100 per cent of the shares in Cardio Dépôt, a niche distributor of medical devices and consumables within cardiology in France.[Asker_press_release_Cardiodepot.jpg] “We are pleased to do our first add-on acquisition in France which will both broaden the offer of high-quality products to our customers within the cardiology field, as well as strengthen the digital presence with its excellent digital platform. We look forward to contributing to the company’s continued growth and to welcome Cardio Dépôt to the Asker team”, says Johan Falk, CEO Asker

    Notice of Extraordinary General Meeting in Asker Healthcare Group AB (publ)

    Asker Healthcare Group AB (publ), Reg. No. 559184-9848 (“Asker” or the “Company”), with its registered office in Danderyd, gives notice of the Extraordinary General Meeting to be held on 9 December 2025 at 09.00 CET at the premises of Advokatfirman Vinge at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 08.30 CET. Right to participate in the Extraordinary General Meeting and notice of participation Participation in the Extraordinary General Meeting at the venue A shareholder who wishes to participate in the Extraordinary General Meeting at the venue, in

    Interogo Holding announces intragroup transfer of its shares in Asker from Nalka Invest to its long-term equity strategy; and Nomination Committee proposes new board member

    Today, Interogo Holding (“Interogo”), the parent company of Asker’s main owner Nalka Invest, announced the intention to move its entire holding in Asker Healthcare Group to its long-term equity strategy. The possibility of an intragroup transfer of the shares within the Interogo Holding group was communicated in connection with Asker’s IPO earlier this year. “We continue to view Asker as a long-term hold. The company has had a strong journey and development together with Nalka as the majority and controlling owner. With the significant growth of the business and listing of Asker, the

    Interim Report 1 January–30 September 2025

    Strong third quarter with earnings growth of 25 percent, of which 6 percent organic 1 July–30 September 2025 · Net sales amounted to SEK 4,129m (3,597), up 15 percent. · Adjusted EBITA amounted to SEK 383m (306), up 25 percent, of which 6 percent was organic growth. · The adjusted EBITA margin was 9.3 percent (8.5). · EBIT amounted to SEK 242m (212), and profit for the quarter amounted to SEK 146m (81). · Earnings per share before and after dilution amounted to SEK 0.37 (0.14). · Return on net working capital (EBITA/NWC) amounted to 66.5 percent (66.3). · Cash flow

    Acquisition of InnoMedicus

    Asker Healthcare Group has acquired 100 per cent of the shares in InnoMedicus AG, a niche distributor specialising in devices and solutions for precise diagnostics and minimally invasive therapies within urology, based in Switzerland.[Image.jpg] “We are delighted to welcome InnoMedicus and their talented team to the Asker family. Their extensive expertise and high-quality products and services have earned the trust of leading surgeons and urologists across Europe. By joining forces, we will further strengthen our ability to deliver value to healthcare providers and patients throughout

    Invitation to Asker Healthcare Group’s Q3 2025 webcast

    Asker Healthcare Group will publish its interim report for January-September 2025 on 6 November, at 08:10 CET.Asker invites investors, analysts and media to a webcast presentation on the same day at 10:00 CET. Asker’s CEO Johan Falk and CFO Thomas Moss will present and comment on the report, followed by a Q&A session.   You will find the webcast link via Q3 Report 2025 .    To participate via phone and ask questions, please register via Call Access .

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe